BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA (zanubrutinib) reinforce potential across various B-cell malignancies Early results for BTK-targeted CDAC (BGB-16673)